Skeletal muscle depletion and markers for cancer cachexia are strong prognostic factors in epithelial ovarian cancer

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Aust, Stefanie ^a   Knogler, Thomas ^a   Pils, Dietmar ^a   Obermayr, Eva ^a   Reinthaller, Alexander ^a   Zahn, Lisa ^a   Radlgruber, Ilja ^a   Mayerhoefer, Marius Erik ^a   Grimm, Christoph ^a   Polterauer, Stephan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EOTAXIN; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; PLATINUM COMPLEX; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; TUMOR MARKER;

ARTICLE; BODY COMPOSITION; CACHEXIA; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARY CARCINOMA; PROTEIN BLOOD LEVEL; SKELETAL MUSCLE; AGED; BLOOD; COMPLICATION; DIAGNOSTIC IMAGING; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PROGNOSIS; RADIOGRAPHY;

AGED; BIOMARKERS, TUMOR; BODY COMPOSITION; CACHEXIA; CYTOKINES; FEMALE; HUMANS; MIDDLE AGED; MUSCLE, SKELETAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RADIOGRAPHY;

EID: 84948987260     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140403     Document Type: Article

References (39)

1. Faber J, Vos AP, Kegler D, Argiles J, Laviano A, Garssen J, et al. Impaired immune function: An early marker for cancer cachexia. Oncology reports. 2009; 22(6):1403-6. PMID: 19885593.
2. Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: Understanding the molecular basis. Nature reviews Cancer. 2014; 14(11):754-62. doi: 10.1038/nrc3829 PMID: 25291291.
3. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013; 31(12):1539-47. Epub 2013/03/27. doi: 10.1200/JCO.2012.45.2722 [pii]. PMID: 23530101.
4. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: Estimation from a single abdominal cross-sectional image. J Appl Physiol (1985). 2004; 97(6):2333-8. Epub 2004/08/18. doi: 10.1152/japplphysiol.00744.2004 [pii]. PMID: 15310748.
5. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age and ageing. 2010; 39(4):412-23. doi: 10.1093/ageing/afq034 PMID: 20392703; PubMed Central PMCID: PMC2886201.
6. Delmonico MJ, Harris TB, Lee JS, Visser M, Nevitt M, Kritchevsky SB, et al. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc. 2007; 55(5):769-74. Epub 2007/05/12. JGS1140 [pii] doi: 10.1111/j.1532-5415.2007.01140.x PMID: 17493199.
7. McNamara MJ, Alexander HR, Norton JA. Cytokines and their role in the pathophysiology of cancer cachexia. JPEN Journal of parenteral and enteral nutrition. 1992; 16(6 Suppl):50S-5S. PMID: 1287224.
8. Suzuki H, Asakawa A, Amitani H, Nakamura N, Inui A. Cancer cachexia-pathophysiology and management. J Gastroenterol. 2013; 48(5):574-94. Epub 2013/03/21. doi: 10.1007/s00535-013-0787-0 PMID: 23512346; PubMed Central PMCID: PMC3698426.
9. Argiles JM, Busquets S, Lopez-Soriano FJ. Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care. 2003; 6(4):401-6. PMID: 12806213.
10. Argiles JM, Busquets S, Garcia-Martinez C, Lopez-Soriano FJ. Mediators involved in the cancer anorexia-cachexia syndrome: Past, present, and future. Nutrition. 2005; 21(9):977-85. doi: 10.1016/j. nut.2005.02.003 PMID: 16043325.
11. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol. 1997; 66(1):27-30. doi: 10.1006/gyno.1997.4726 PMID: 9234916.
12. Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Buchler MW, Friess H, Martignoni ME. Cachexia worsens prognosis in patients with resectable pancreatic cancer. Journal of gastrointestinal surgery: Official journal of the Society for Surgery of the Alimentary Tract. 2008; 12(7):1193-201. doi: 10.1007/s11605-008-0505-z PMID: 18347879.
13. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 2005; 8(3):265-9. Epub 2005/04/06. 00075197-200505000-00005 [pii]. PMID: 15809528.
14. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 2011; 12(5):489-95. Epub 2011/02/08. doi: 10.1016/S1470-2045(10)70218-7 [pii]. PMID: 21296615.
15. Aust S, Horak P, Pils D, Pils S, Grimm C, Horvat R, et al. The prognostic value of estrogen receptor beta and proline-, glutamic acid-and leucine-rich protein 1 (PELP1) expression in ovarian cancer. BMC cancer. 2013; 13:115. doi: 10.1186/1471-2407-13-115 PMID: 23497172; PubMed Central PMCID: PMC3605348.
16. Weissman AD, Broussolle EP, London ED. In vivo binding of [3H]d-N-allylnormetazocine and [3H]haloperidol to sigma receptors in the mouse brain. Journal of chemical neuroanatomy. 1990; 3(5):347-54. PMID: 2171560.
17. Aubrey J, Esfandiari N, Baracos VE, Buteau FA, Frenette J, Putman CT, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta physiologica. 2014; 210(3):489-97. doi: 10.1111/apha.12224 PMID: 24393306.
18. Harrell FE. Regression modeling strategies: With applications to linear models, logistic regression, and survival analysis. New York: Springer; 2001. xxii, 568 p. p.
19. Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. Journal of clinical epidemiology. 1996; 49(8):907-16. PMID: 8699212.
20. Royston P, Altman DG. Regression using fractional polynomials of continuous covariates: Parsimonious parametric modelling. Appl Statist. 1994; 43(3):429-67.
21. Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer: Lessons from morphology and molecular biology and their clinical implications. International journal of gynecological pathology: Official journal of the International Society of Gynecological Pathologists. 2008; 27(2):151-60. PMID: 18317228; PubMed Central PMCID: PMC2794425.
22. Argiles JM, Moore-Carrasco R, Fuster G, Busquets S, Lopez-Soriano FJ. Cancer cachexia: The molecular mechanisms. The international journal of biochemistry & cell biology. 2003; 35(4):405-9. PMID: 12565701.
23. Block MS, Maurer MJ, Goergen K, Kalli KR, Erskine CL, Behrens MD, et al. Plasma immune analytes in patients with epithelial ovarian cancer. Cytokine. 2015; 73(1):108-13. doi: 10.1016/j.cyto.2015.01. 035 PMID: 25743245.
24. Goodpaster BH, Thaete FL, Kelley DE. Composition of skeletal muscle evaluated with computed tomography. Ann N Y Acad Sci. 2000; 904:18-24. PMID: 10865705.
25. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol. 2008; 9(7):629-35. doi: 10.1016/S1470-2045(08) 70153-0 PMID: 18539529.
26. Antoun S, Lanoy E, Iacovelli R, Albiges-Sauvin L, Loriot Y, Merad-Taoufik M, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013; 119(18):3377-84. doi: 10.1002/cncr.28218 PMID: 23801109.
27. Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S, Wang S. Sarcopenia as a prognostic factor among patients with stage III melanoma. Annals of surgical oncology. 2011; 18(13):3579-85. doi: 10.1245/s10434-011-1976-9 PMID: 21822551.
28. Nick AM, Coleman RL, Ramirez PT, Sood AK. A framework for a personalized surgical approach to ovarian cancer. Nature reviews Clinical oncology. 2015. doi: 10.1038/nrclinonc.2015.26 PMID: 25707631.
29. Asher V, Lee J, Bali A. Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer. Medical oncology. 2012; 29(3):2005-9. doi: 10.1007/s12032-011-0019-5 PMID: 21735143.
30. Merlot AM, Kalinowski DS, Richardson DR. Unraveling the mysteries of serum albumin-more than just a serum protein. Frontiers in physiology. 2014; 5:299. doi: 10.3389/fphys.2014.00299 PMID: 25161624; PubMed Central PMCID: PMC4129365.
31. Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JC, Hartung G, et al. Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and the genesis of cachexia. Critical reviews in oncology/hematology. 1997; 26(2):77-100. PMID: 9298326.
32. Neven B, Mamessier E, Bruneau J, Kaltenbach S, Kotlarz D, Suarez F, et al. A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency. Blood. 2013; 122(23):3713-22. doi: 10.1182/blood-2013-06-508267 PMID: 24089328.
33. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. The Journal of clinical investigation. 1996; 98(4):1010-20. doi: 10.1172/JCI118861 PMID: 8770874; PubMed Central PMCID: PMC507517.
34. Acuner-Ozbabacan ES, Engin BH, Guven-Maiorov E, Kuzu G, Muratcioglu S, Baspinar A, et al. The structural network of Interleukin-10 and its implications in inflammation and cancer. BMC genomics. 2014; 15 Suppl 4:S2. PMID: 25056661; PubMed Central PMCID: PMC4083408.
35. Santin AD, Bellone S, Ravaggi A, Roman J, Smith CV, Pecorelli S, et al. Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG: An international journal of obstetrics and gynaecology. 2001; 108(8):804-8. PMID: 11510703.
36. Tsai-Turton M, Santillan A, Lu D, Bristow RE, Chan KC, Shih Ie M, et al. p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol. 2009; 114(1):12-7. doi: 10.1016/j.ygyno.2009.03. 028 PMID: 19398128; PubMed Central PMCID: PMC2694938.
37. Rankin SM, Conroy DM, Williams TJ. Eotaxin and eosinophil recruitment: Implications for human disease. Molecular medicine today. 2000; 6(1):20-7. PMID: 10637571.
38. Levina V, Nolen BM, Marrangoni AM, Cheng P, Marks JR, Szczepanski MJ, et al. Role of eotaxin-1 signaling in ovarian cancer. Clinical cancer research: An official journal of the American Association for Cancer Research. 2009; 15(8):2647-56. doi: 10.1158/1078-0432.CCR-08-2024 PMID: 19351767; PubMed Central PMCID: PMC2669845.
39. Koc U, Cetinkaya E, Bostanci EB, Kemik AS, Tez M, Gomceli I, et al. Diagnostic significance of serum eotaxin-1 level in gastric cancer patients. Disease markers. 2013; 35(5):363-7. doi: 10.1155/2013/274515 PMID: 24223454; PubMed Central PMCID: PMC3810232.